18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: Tumour-to-liver ratio is superior to an SUVmax cut-off

European Radiology

Volumn 24, Issue 2, 2014, Pages 405-412

  Salamon, Johannes ^a   Veldhoen, Simon ^a,b   Apostolova, Ivayla ^c   Bannas, Peter ^a   Yamamura, Jin ^a   Herrmann, Jochen ^a   Friedrich, Reinhard E ^a   Adam, Gerhard ^a   Mautner, Victor F ^a   Derlin, Thorsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

MPNST; Neurofibromatosis; NF1; PET; Ratio

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GASTROLUX CT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MIDDLE AGED; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 1; PET-CT SCANNER; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; TUMOR LOCALIZATION; TUMOR TO LIVER RATIO; TUMOR VOLUME; YOUNG ADULT; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; IMAGE PROCESSING; METABOLISM; METHODOLOGY; NERVE SHEATH TUMOR; PERIPHERAL NERVE TUMOR; POSITRON EMISSION TOMOGRAPHY; SKELETAL MUSCLE;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NEOPLASM STAGING; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84893323110     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-013-3020-x     Document Type: Article

References (34)

1. Listernick R, Charrow J (1990) Neurofibromatosis type 1 in childhood. J Pediatr 116:845-853
2. Conference Statement (1988) Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45:575-578
3. Ramanathan RC, Thomas JM (1999) Malignant peripheral nerve sheath tumours associated with von Recklinghausen's neurofibromatosis. Eur J Surg Oncol 25:190-193
4. McGaughran JM, Harris DI, Donnai D et al (1999) A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 36:197-203
5. Ferner RE, Gutmann DH (2002) International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 62:1573-1577
6. Ducatman BS, Scheithauer BW, Piepgras DG et al (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57:2006-2021
7. Evans DGR, Baser ME, McGaughran J et al (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311-314
8. Lawrence W, Donegan WL, Natarajan N et al (1987) Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg 205:349-359
9. Korf BR (1999) Plexiform neurofibromas. Am J Med Genet 89:31-37
10. Mautner VF, Hartmann M, Kluwe L et al (2006) MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology 48:160-165
11. Tucker T, Wolkenstein P, Revuz J et al (2005) Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 65:205-211
12. Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50:11S-20S
13. Jaskowiak CJ, Bianco JA, Perlman SB, Fine JP (2005) Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. J Nucl Med 46:424-428
14. Warbey VS, Ferner RE, Dunn JT et al (2009) [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 36:751-757
15. Ferner RE, Golding JF, Smith M et al (2008) [18F]2-fluoro-2-deoxy-D- glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 19:390-394
16. Brenner W, Friedrich RE, Gawad KA et al (2006) Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 33:428-432
17. Benz MR, Czernin J, Dry SM et al (2010) Quantitative F18- fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer 116:451-458
18. Salamon J, Derlin T, Bannas P et al (2012) Evaluation of intratumoural heterogeneity on (18)F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging 40:685-692
19. Lindholm P, Minn H, Leskinen-Kallio S et al (1993) Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 34:1-6
20. Visvikis D, Cheze-LeRest C, Costa DC et al (2001) Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET. Eur J Nucl Med 28:1326-1335
21. Thie JA (2004) Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45:1431-1434
22. Meignan M, Gallamini A, Haioun C (2009) Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma 50:1257-1260
23. Barrington SF, Qian W, Somer EJ et al (2010) Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:1824-1833
24. Lee JW, Paeng JC, Kang KW et al (2009) Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 50:682-687
25. Trojani M, Contesso G, Coindre JM et al (1984) Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 33:37-42
26. Lin BT, Weiss LM, Medeiros LJ (1997) Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. Am J Surg Pathol 21:1443-1449
27. Treglia G, Taralli S, Bertagna F et al (2012) Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with neurofibromatosis type 1: a systematic review. Radiol Res Pract 2012:431029
28. Khan MA, Combs CS, Brunt EM et al (2000) Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32:792-797
29. Furth C, Amthauer H, Hautzel H et al (2011) Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma - results for dedicated assessment criteria in a blinded dual-centre read. Ann Oncol 22:1198-1203
30. Eary JF, Link JM, Muzi M et al (2011) Multiagent PET for risk characterization in sarcoma. J Nucl Med 52:541-546
31. Buck AK, Herrmann K, Büschenfelde CM zum et al (2008) Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine. Clin Cancer Res 14:2970-2977
32. Wasa J, Nishida Y, Tsukushi S et al (2010) MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. AJR Am J Roentgenol 194:1568-1574
33. Matsumine A, Kusuzaki K, Nakamura T et al (2009) Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol 135:891-900
34. Derlin T, Tornquist K, Münster S et al (2013) Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med 38:e19-e25